广济药业: 关于公开挂牌转让湖北广济医药科技有限公司90%股权进展暨完成工商变更登记的公告

Transaction Overview - Hubei Guangji Pharmaceutical Co., Ltd. announced the public transfer of 90% equity in its subsidiary Hubei Guangji Pharmaceutical Technology Co., Ltd. through the Shanghai United Assets and Equity Exchange [1][2] - The transfer price is set at RMB 44.7856 million, based on the assessed value of the equity [2][3] Transaction Progress - As of the announcement date, the company has received the property transaction certificate from the Shanghai United Assets and Equity Exchange, and the buyer has paid the full transaction price [4] - The subsidiary has completed the business registration change and obtained a new business license, now named Hubei Changjiang Ruiyi Pharmaceutical Technology Co., Ltd. [4] Post-Transaction Status - Following the completion of the business registration change, the company no longer holds shares in Hubei Changjiang Ruiyi Pharmaceutical Technology Co., Ltd. and will not consolidate it into its financial statements [5]